MYC and breast cancer: However, to increase the stringency and to make a conservative choice about which of these are most likely true positive CNV events, we chose only the 79 CNVs which were also reported by Zack et al. [7] to be highly recurrent in breast cancers (e.g., the amplification of the MYC oncogene at 8q24.21) as ground truth (based on biology with high stringency) for our evaluation study.